Physician profile
Ignacio Sanz
NPI 1780601872
$67,749.99
in general payments reported to CMS, 2019-2025
11 companies · $26K in 2025
The $26K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2021: $4,475 · 2022: $4,618 · 2024: $9,674 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Travel and Lodging: $760 · Food and Beverage: $467 · Education: $53.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $34,496.50 |
| Travel and Lodging | $759.51 |
| Food and Beverage | $467.23 |
| Education | $53.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $22,634.44 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16,342.31 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $9,380.00 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $6,526.01 | 2022-2025 | |
| Janssen Research & Development, LLC | $4,500.00 | 2022 | |
| Merck Sharp & Dohme LLC | $4,185.00 | 2025 | |
| Otsuka Pharmaceutical Co., Ltd. | $2,246.28 | 2019-2021 | |
| Sanofi US Services INC. | $1,822.50 | 2024 | |
| Celgene Corporation | $60.00 | 2025 | |
| Genentech, INC. | $53.45 | 2025 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ignacio Sanz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.